Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotro...(s a statistical significance between the...),Health

Date:5/20/2008

s a statistical significance between the mean transitional dyspnea index scores in the Perforomist(TM)/TIO and TIO/placebo groups (2.30 and 0.16, respectively; p=0.0002). Shortness of breath, chest tightness, nighttime awakenings, and total symptom scores all improved significantly with the Perforomist(TM)/TIO treatment compared with TIO/placebo (p<0.05). Cough scores did not differ between groups. Albuterol use declined in the Perforomist(TM)/TIO group from 2.4 to1.3 puffs/day and increased in the TIO/placebo group from 2.8 to 3.4 puffs/day over six weeks; another statistically significant difference (p< 0.0001). SGRQ total scores did not change markedly from baseline or differ between groups except for the symptom domain score, which was superior in the Perforomist(TM)/TIO group compared to TIO/placebo (-6.3, p<0.04).

"DEY is very pleased with the results of this study and the benefit that patients are seeing with Perforomist(TM) Inhalation Solution," said Carolyn Myers, Ph.D., President of Dey, L.P. "We wish to thank Dr. Tashkin and the other members of the research team for their careful investigation into the clinical benefits of concomitant therapy of Perforomist and tiotropium. At DEY, we are committed to developing effective new treatments for serious and complex diseases, and with Perforomist are proud to provide physicians and patients a twice-daily COPD maintenance medication that offers the flexibility of dosing via nebulization."

For those attending ATS 2008, the presentation is available as follows:

Poster viewing: Session ID C42 COPD Pharmacotherapy I: Effects of

Bronchodilators

Tuesday, May 20, 2008, 10:45 a.m. - 12:30 p.m. EDT

Metro Toronto Convention Center; Area F: Halls A-B North Building,

Level 300

Poster # F4: Addition of Nebulized Formoterol Fumarate to Tiotropium

Treatment Relieves Dyspnea and Symptoms in COPD Patients

The research presented at ATS 2008 was supported throu
'/>"/>

SOURCE Dey, L.P. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Clinical Trial Data on the Safety and Efficacy of Concomitant Formoterol Fumarate/ Tiotropium Treatment for COPD
2. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
3. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
4. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
5. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
6. New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
7. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
8. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
9. Gene Therapy Provides Vision to People who Were Nearly Blind
10. Arpida Provides Further Comments on the Pivotal Phase III Trials
11. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology